New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:44 EDTSNSSSunesis raises $43M in common stock and warrants offering
Sunesis announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0M. Cowen and Company, LLC and Cantor Fitzgerald & Co. are acting as Joint Book-Running Managers in this offering.
News For SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
16:04 EDTSNSSSunesis Chief Medical Officer Adam Craig to step down at end of year
Subscribe for More Information
16:03 EDTSNSSSunesis to submit MAA for vosaroxin with EMA by end of 2015
Sunesis Pharmaceuticals announced that the company intends to submit a Marketing Authorization Application for vosaroxin as a treatment for acute myeloid leukemia with the European Medicines Agency by the end of 2015. The company recently announced that it met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guidance to the company through the MAA process. Based on these discussions, the company is proceeding with an MAA filing for the indication of relapsed/refractory AML in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company's pivotal Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory AML.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use